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1875-9572/Copyright ª 2014, TaiwanFentanyl is a synthetic opioid that is very important in anesthetic practice because of its rela-
tively short time to peak analgesic effect and the rapid termination of action after small bolus
doses. The objective of this survey is to review the clinical pharmacology of fentanyl in pre-
term infants. The bibliographic search was performed using PubMed and EMBASE databases
as search engines. In addition, the books Neofax: A manual of drugs used in neonatal care
and Neonatal formulary were consulted. Fentanyl is N-dealkylated by CYP3A4 into the inactive
norfentanyl. Fentanyl may be administered as bolus doses or as a continuous infusion. In neo-
nates, there is a remarkable interindividual variability in the kinetic parameters. In neonates,
fentanyl half-life ranges from 317 minutes to 1266 minutes and in adults it is 222 minutes. Res-
piratory depression occurs when fentanyl doses are >5 mg/kg. Chest wall rigidity may occur in
neonates and occasionally is associated with laryngospasm. Tolerance to fentanyl may develop
after prolonged use of this drug. Significant withdrawal symptoms have been reported in in-
fants treated with continuous infusion for 5 days or longer. Fentanyl is an extremely potent
analgesic and is the opioid analgesic most frequently used in the neonatal intensive care unit.
Copyright ª 2014, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
The mainstay of systemic analgesia for moderate to severe
pain is the use of opioid therapy. Opioids provide both
sedation and analgesia, have a wide therapeutic window,
and decrease hemodynamic and metabolic stress
response.1 As pain is a major stressor that may increaseSchool, Via Roma 55, 56126 Pisa,
nipi.it.
014.06.002
Pediatric Association. Published bmorbidity and mortality in critically ill neonates,2 sedation
and analgesia are widely used in infants.2 Fentanyl is the
most used analgesic opioid in the neonatal intensive care
unit. Fentanyl acts as an agonist binding to m and k opioid
receptors and has the properties of an analgesic, sedative,
and anesthetic.3 This drug has a rapid onset of action of
2e3 minutes, a short duration of action of 60 minutes withItaly.
y Elsevier Taiwan LLC. All rights reserved.
144 G.M. Pacificibolus doses and minimal hemodynamic effects.4 It is widely
used to provide rapid short-lived pain relief during surgery.5
This drug is 50e100-times more potent than morphine on a
weight basis.3 In the literature, there was no survey on the
clinical pharmacology of fentanyl in preterm infants,
although this drug is often used in neonates. This prompted
us to review the published data on the effects and fate of
fentanyl in neonates, and to write the present article. The
objective of this study is to review the clinical pharma-
cology of fentanyl in preterm infants.
2. Bibliographic search
The bibliographic search was performed electronically using
PubMed and EMBASE databases as search engines. The
following keywords were used: “fentanyl pharmacokinetics
neonate”, “fentanylmetabolismneonate”, “CYP3A4 fentanyl
neonate”, “fentanyl adverse effects neonate”, “chest wall
rigidity fentanyl neonate”, “muscle rigidity fentanyl
neonate”, “urinary retention fentanyl neonate”, “hypother-
mia fentanyl neonate”, “pharmacodynamic-pharmacokinetic
fentanyl neonate”, “tolerance fentanyl neonate”, and
“adverse effects fentanyl neonate”. In addition, the books
Neofax: Amanual of drugs used in neonatal care byYoung and
Mangum6 and the Neonatal formulary7 were consulted. Drug
use in pregnancy and the first year of life.
3. Results
3.1. Effects of fentanyl in neonates
Fentanyl is an extremely potent analgesic, maintains he-
modynamic stability, blocks endocrine stress responses,
and prevents pain-induced and increased pulmonary
vascular resistance.2,8 Muscle rigidity appears after high
doses of fentanyl used in anesthetic induction.9e12 Rigidity
and respiratory depression can be treated with naloxone
(10 mg/kg).3 High doses of fentanyl can cause neuro-
excitation and, rarely, seizure-like activity.9
Guinsburg et al13 studied the response of 22 ventilated
preterm infants prior to and after a single dose of 3 mg/kg
fentanyl or placebo, and evaluated the physiologic and
behavioral measures for the assessment of pain in intu-
bated and ventilated preterm infants, and also studied
their physiologic and behavioral pain responses occurring
after fentanyl analgesia. The work by Guinsburg et al13
suggests that opioid use may decrease catabolism, divert
energy sources to growth and healing, and have a beneficial
effect on the clinical stability of critical ill preterm infants.
Single doses of fentanyl analgesia can reduce the physio-
logic/behavioral measures of pain and stress associated
with mechanical ventilation in preterm infants.
Recently, attention was drawn to the pharmacokinetic/
pharmacodynamic (PK/PD) relationship for fentanyl. A
predictive PK/PD model of fentanyl that includes growth
and maturation physiologic changes for fentanyl in neo-
nates was developed.14 The final model was evaluated by
predicting the time course of plasma concentrations and
the effect of a standard regimen of 10.5 mg/kg, followed by
1.5 mg/kg/hour for 48 hours. Systemic clearance, volume ofdistribution of the central compartment, and steady-state
volume of distribution were 0.028 L/minute, 1.26 L, and
22.04 L, respectively. The model could be used in optimal
design of clinical trials for this vulnerable population.
The PK/PD correlation of intranasal and intravenous
fentanyl in opioid-naı¨ve patients has been studied.15
Bioavailability of intranasal fentanyl was 89%, with a lag
of approximately 5 minutes and a half-life of about 6.5
minutes. Interindividual variability of fentanyl was about
30% for all absorption parameters. Intranasal versus intra-
venous administration of fentanyl lead to a delayed mean
fentanyl time to maximum concentration (13 minutes vs. 6
minutes) and lower maximum concentration (1.2 ng/mL vs.
2.0 ng/mL). Dosing of intranasal fentanyl can be variable
and the duration of effect was directly related to the
intranasal fentanyl dose. The standard dose of intrave-
nously administered fentanyl is 1e2 mg/kg.
Changes in plasma fentanyl concentrations were
measured in 15 infants undergoing cardiac surgery using
a low-volume bypass circuit.16 Intravenous anesthesia
was induced with 30 mg/kg of fentanyl, followed by a
continuous infusion of 0.3 mg/kg fentanyl/hour until skin
closure. Minimal changes in fentanyl concentration occur
during infant cardiac surgery when a low-volume circuit
and a fentanyl technique that includes an initial bolus
followed by a continuous infusion of fentanyl are used.
3.2. Metabolism of fentanyl in neonates and adults
Fentanyl is metabolized by CYP3A4,3 which appears during
the 1st week of life.6,7 Studies with the human adult liver
microsomes revealed that fentanyl is N-dealkylated to give
the inactive norfentanyl.17 Fentanyl is also N-hydroxylated
by CYP3A4, but N-hydroxylation is a minor metabolic
pathway of fentanyl.18
Tramodol (M) is N-demethylated to N-demethyl tramadol
(M2) by CYP3A4. The log M/M2 ratio was assessed in 24-hour
urine collection and found to be 1.44  0.46. There was an
inverse correlation with the postmenstrual age
(r2 Z 0.43)19 and the maturational half-life of the log M/
M2 ratio was 16e20 weeks. The postmenstrual age was
found to be the most important maturational change
determining the in vivo activity of CYP3A4.19
3.3. Pharmacokinetics following bolus
administration of fentanyl to neonates
The pharmacokinetic parameters of fentanyl are summa-
rized in Table 1.
Fentanyl is well absorbed by the gastrointestinal tract, but
bioavailability is limited by rapid liver metabolism.5,20 The
pharmacokinetics of fentanyl, administered intravenously at
the doses 10e50 mg/kg, were studied in 14 neonates aged
1e14 days, undergoing major surgical procedures.18 Phar-
macokinetics of fentanylwere influenced neither by thedose,
nor by the infant age. Doses of 25e50 mg/kg fentanyl given to
infants aged 0.5e1 day yielded plasma concentrations of
1.1e3.8 ng/mL 3e16 hours after fentanyl injection.18
The pathology and/or the surgical lesion lengthen half-life
of fentanyl.18 Three infants with increased intra-abdominal
pressure had a fentanyl half-life 1.5e3 times the population
Table 1 Pharmacokinetic parameters of fentanyl in neonates.
Age (d) No. of cases Dose (mg/kg) Half-life (min) Clearance (mL/min/kg) Distribution volume (l/kg) Refs
1e14 14 10e50 Bolus 317  70* 17.9  4.4* 5.1  1.0* 18
1e71 14 54.1  2.3 Bolus 279  204 19.2  11.0 8.2  2.5 25
31.8  4.7 weeks 9 30 Bolus 1062  558 NA NA 26
26e42 weeks 38 Infusiony NA 11.5  4.0 NA 30
32  4 weeks 7 1.28  0.58 mg/kg/h 570  156 19.2  8.2 17.0  9.0 31
18 dayse14 years 19 Bolus þ infusionx 1266z 13.2y 15.2y 27
Adults d d 222  24 13.2  2.0 4.0  0.4 28
Data are presented as mean  standard deviation unless otherwise indicated.
NA Z not available.
* Data are the mean  standard error of the mean.
y Continuous infusion of fentanyl of 10.5 mg/kg over a 1-hour period was followed by an infusion of 1.5 mg/kg/hour for 2e3 days.
z Value is presented as mean as standard deviation was not available.
x Loading dose of 5 mg/kg fentanyl, immediately followed by a constant infusion at 0.47e10.3 mg/kg/hour.
Fentanyl in preterm infants 145mean of 317 minutes.18 An infant, treated with 25 mg/mL and
undergoing an exploratory laparotomy, had a fentanyl half-
life of 750 minutes.18 Another infant, who received 50 mg/kg
fentanyl, andwas undergoing a repair of a large omphalocele,
had a fentanyl half-life of 463 minutes.18
Neonates with increased abdominal pressure had longer
half-life than healthy infants. Fentanyl has a high hepatic
extraction ratio, and clearance is primarily dependent on
hepatic perfusion.18 The transient rebounds in fentanyl
plasma levels that occurred in some patients may reflect
sequestering and subsequent release of fentanyl. Rebounds
in fentanyl plasma levels have been reported in adults.21e24
Fentanyl was administered at the dosage of
54.1  2.3 mg/kg to 14 infants aged from 1 day to 71 days.25
Clearance was not measurable in two neonates aged 1 day
and 3 days. In the remaining 12 neonates, clearance ranged
from 9.0 mL/kg/minute to 32.8 mL/kg/minute
[mean  standard deviation (SD), 19.2  11.0 mL/kg/mi-
nutes) and was correlated with the infant age (r Z 0.5642;
p Z 0.0356). Mean  SD half-life was 279  204 minutes
and distribution volume was 8.2  2.5 L/kg. Neither
parameter was correlated with the infant’s age.
Fentanyl (30 mg/kg) was administered to nine preterm
infants.26 The fentanyl plasma concentration was
10.6  1.9 ng/mL, 30 minutes after dosing. After 2 hours, it
was 9.6  1.6 ng/mL suggesting that fentanyl plasma con-
centration reduces slowly in infants yielding a half-life of
1062  558 minutes.
A gradual increase in heart rate from 159  12 beats/
minute, at the time of skin incision, to 173  15 beats/
minutes (p < 0.05), at the time of skin closure,26 was
observed after fentanyl injection. A 30-mg/kg dose of fen-
tanyl may not be adequate to cover the increased stimulus
of skin closure in preterm infants after closure of a patent
ductus arteriosus. A dose of 50 mg/kg or a continuous
infusion of fentanyl are more reasonable.
The unbound fentanyl fraction is 0.23 in neonatal
plasma27 and 0.16 in adult plasma.28 The modest difference
in the unbound fraction of fentanyl between infants and
adults cannot explain the large difference observed in
distribution volume between neonates and adults. The
rapid and cumulative redistribution of fentanyl into fat and
muscle depots may be the cause of the large distribution
observed in neonates.53.4. Pharmacokinetics following continuous
infusion of fentanyl to neonates
Thirty-eight infants with a gestational age of 26e42 weeks
received a fentanyl bolus dose of 10.5 mg/kg, followed by
an infusion of 1.5 mg/kg/hour, which lasted for 2e3 days.29
The steady-state fentanyl concentration (mean  SD,
2.5  1 ng/mL) negatively correlated with the pain score
(r Z 0.57; p < 0.01). The clearance of fentanyl
(mean  SD, 11.5  4.0 mL/kg/minute) correlated with
gestational age (r Z 0.46; p < 0.01) and with birth weight
(r Z 0.48; p < 0.01).
The pharmacokinetics of fentanyl was studied in seven
preterm infants30 who had undergone mechanical ventila-
tion. They received a continuous infusion of fentanyl
(mean  SD, 1.28  0.58 mg/kg/hour). The mean half-life,
clearance, and distribution volume were 570  156 mi-
nutes, 19.2  8.2 mL/minute/kg, and 17.0  9.0 L/kg,
respectively. A significant correlation was observed be-
tween postnatal age and clearance (r Z 0.80; p Z 0.03).
Nineteen children, aged from 18 days to 14 years, un-
dergoing mechanical ventilation, received a loading dose of
5 mg/kg fentanyl, followed by a continuous infusion of
3.6 mg/kg/hour.31 Clearance was 13.2  2.0 mL/minute/kg
and correlated with infant age. Patients aged between 6
months and 6 years had a mean clearance of 18.8 mL/
minute/kg and patients aged <6 months and >6 years had a
clearance of 8.0 mL/minute/kg and 8.1 mL/minute/kg,
respectively. The mean terminal half-life was 1266 minute
and distribution volume was 15.2 L/kg. Patients seen in a
pediatric intensive care unit required a 10-fold variability in
fentanyl infusion rates to achieve similar levels of sedation.
3.5. Analgesic effects of fentanyl following bolus or
continuous infusion to neonates
Ancora et al32 studied the analgesic effect of fentanyl in
64 preterm infants. There were 67 controls and the study
lasted 7 days. The analgesic efficacy was evaluated by the
Echelle Douleur Inconfort Nouveau-Ne` scale, with scores
>6 for 6.8% (fentanyl) and 10.6% (placebo; p Z 0.003).
The median premature infant pain profile score was sta-
tistically higher in the placebo group than in the fentanyl
146 G.M. Pacificigroup on Day 1, Day 2, and Day 3 after treatment
(p < 0.05). Mechanical ventilation was required in 42.2%
and 25.4% (p Z 0.042) in the fentanyl group and placebo
group, respectively. The median duration of the me-
chanical ventilation cycle was 151 hours and 110 hours
(p Z 0.019) in the fentanyl group and placebo group,
respectively. In preterm infants on mechanical ventila-
tion, continuous fentanyl infusion, plus open-label boluses
of fentanyl, does not reduce prolonged pain, and in-
creases adverse effects compared with open-label boluses
of fentanyl alone. Vaughn et al33 compared the continuous
infusion of fentanyl with bolus dosing in infants. Apnea
occurred in eight of nine (89%) patients receiving fentanyl
as a bolus compared with one of seven patients receiving
fentanyl as a continuous infusion (14%; p < 0.009). Apnea
was less likely to be severe in the continuous infusion
patients (11%) than in the bolus patients (73%). Bolus
fentanyl dosing may be appropriate for analgesia and
sedation during minor procedures, but is not appropriate
for postoperative analgesia in high-risk neonates.
Continuous infusion of fentanyl is not a therapy without
risk, but it may be associated with less severe respiratory
depression as compared with intermittent treatment. The
results by Ancora et al32 do not accord with those by
Vaughn et al.33
Gruber et al34 evaluated whether the administration of
midazolam has some beneficial effects compared to that
obtained with large-dose fentanyl. These authors were
unable to demonstrate any additional suppression of the
stress response in the midazolam group, or advantages in
hemodynamic stability or total duration of mechanical
ventilation and intensive care unit stay.3.6. Plasma levels of fentanyl during
extracorporeal membrane oxygenation in neonates
Extracorporeal membrane oxygenation (ECMO) therapy is a
form of prolonged cardiopulmonary bypass used to support
patients with life-threatening respiratory or cardiac fail-
ure.35 Fentanyl has rapid onset of action, relative hemo-
dynamic effects, and short half-life, and is frequently used
to provide analgesia and sedation for patients undergoing
ECMO therapy. Tolerance to opioid-induced sedation has
been described in neonates sedated with fentanyl by
continuous infusion while undergoing ECMO.36 Eight neo-
nates, with a birth weight of 3160  620 g, received a
fentanyl dose of 10e20 mg/kg, followed by continuous
fentanyl infusion (9.2  1.9 mg/kg/hour), which lasted
5.9  3.0 days. The mean fentanyl infusion rate increased
238% during the 6 days of infusion. The assessment of ad-
equacy of sedation in critically ill newborn infants under-
going ECMO is a difficult process because of the alterations
that occur in infant fentanyl pharmacodynamics.
The neonates who had opioid withdrawal after ECMO,
had significantly higher peak infusion rates of fentanyl,
larger total doses of fentanyl, and longer ECMO therapy
than the neonates who did not have withdrawal after ECMO
(p < 0.001, p Z 0.003, and p Z 0.009, respectively). Ne-
onates who received a total fentanyl dose >1.2 mg/kg
during ECMO were 13 times more likely to experience opioid
withdrawal after ECMO (Fisher exact test, p Z 0.003) thanwere neonates who received a smaller total dose of fen-
tanyl. Total fentanyl dose during ECMO had a sensitivity of
85% and a specificity of 70% for predicting the occurrence of
withdrawal after ECMO. Tolerance and physical depen-
dence are thought to develop more rapidly with continuous
infusion than with intermittent administration, because of
the greater duration of receptor occupancy.37
3.7. Adverse effects of fentanyl in neonates
Fentanyl citrate is incompatible with thiopental sodium,
methohexital sodium,38 azithromycin, pentobarbital so-
dium, and phenytoin.1 Ketoconazole and erythromycin are
potent inhibitors of fentanyl metabolism17 and must not be
used in association with fentanyl.
Nausea, vomiting, and itching can be observed after
fentanyl administration. Muscle rigidity appears to be more
common after high doses used in anesthetic induction. High
doses of fentanyl can cause neuroexcitation and, rarely,
seizure-like activity.5 Urinary retention may occur with
fentanyl continuous infusion.3 Respiratory depression oc-
curs when fentanyl doses >5 mg/kg are used, and it may
also occur unexpectedly because of redistribution.3,39
Respiratory depression responds to naloxone (10 mg/kg).3
Atropine (10e30 mg/kg)3 may be used to block the vagal
effects of fentanyl such as bradycardia.
A study on chest wall rigidity, with occasional lar-
yngospasm, has been reported in preterm and term in-
fants.9 Eight out of 89 neonates receiving fentanyl over a 1-
year period showed chest wall rigidity.12 Fentanyl dosage
ranged from 2.2 mg/kg to 6.5 mg/kg and was administered as
a slow intravenous bolus.12 Seventy-five percent of patients
received naloxone 10e105 mg/kg (mean dose 45 mg/kg),
resulting in improvement and recovery from respiratory
distress with good thoracic expansion after 1 minute.40
Fentanyl analgesia increases the incidence of post-
operative hypothermia in neonates.41,42 Nine neonates with
a mean age of 35 weeks received fentanyl intravenously
(median 5.9 mg/kg). The decrease in temperature was
1.8e2.8C. Hypothermia can increase the risk of post-
operative complications by inducing peripheral vasocon-
striction, increasing anaerobic metabolism, pulmonary
vasoconstriction, and right-to-left shunting. Morphine or
bupivacaine did not yield hypothermia.
Tolerance is an adverse effect of opioids and may
develop to high analgesic doses with prolonged use.36,41
Significant withdrawal symptoms have been reported in
patients treated with continuous infusion receiving
10e20 mg/kg fentanyl for 5 days or longer.1 Arnold et al41
reported the uniform development of tolerance and high
incidence of opioid dependence in neonates receiving
prolonged fentanyl infusion during ECMO. Mean infusion
rate increased steadily during ECMO therapy, from a
mean  SD of 11.6  6.9 mg/kg/hour on Day 1 to
52.5  19.4 mg/kg/hour on Day 8; the increase was 452%.
4. Discussion
Fentanyl provides rapid analgesia, maintains hemostatic
stability, blocks endocrine stress responses, and prevents
pain-induced increases in pulmonary vascular resistance.
Fentanyl in preterm infants 147Fentanyl causes less histamine release than morphine and is
therefore more stable in patients with congenital heart or
chronic lung disease.5
Muscle rigidity appears to be more common after high
doses in anesthetic induction.42e49 Chest rigidity and lar-
yngospasm are reversible with 10 mg/kg naloxone.3 It has
been postulated that the rigidity is mediated in part by the
modulation of g-aminobutyric acid pathways at the spinal
cord and basal ganglia levels via fentanyl binding to m1 and
k opioid receptors.44
Sustained administration of an opiate agonist leads to
progressive loss of drug effect. Tolerance is reflected by a
reduction in the maximum achievable drug effect. It de-
velops rapidly, especially with infusion compared to boluses
because of the greater duration of receptor occupancy.50
A remarkable variability of the pharmacokinetic pa-
rameters of fentanyl has been described in neonates.18
Half-life ranged 12-fold, and distribution volume and
clearance ranged 12-fold and 11-fold, respectively. The
longer half-life of fentanyl in neonates, and the consequent
lower rate of fentanyl elimination, are due to the lower
expression of CYP3A4 in neonatal liver, which metabolizes
fentanyl.7,51 The pathology and/or surgical lesion lengthens
half-life of fentanyl in neonates.
Guinsburg et al13 suggested that preterm neonates
experience some degrees of pain or stress associated with
mechanical ventilation. Opioid use has a beneficial effect
on the clinical stability of critically ill preterm neonates.4,41
Ancora et al32 found that fentanyl administrated as a
bolus is safer that the continuous administration of fenta-
nyl. In contrast, Vaughn et al33 reported opposite results: a
lower frequency of apneic spells after continuous infusion
than after bolus administration of fentanyl.
Tolerance to opioid-induced sedation has been reported
in neonates sedated with fentanyl by continuous infusion
while undergoing ECMO.41 An average of 8 days duration of
ECMO therapy determined an infusion rate increase of
452%. The mean plasma fentanyl concentrations increased
448% in 6 days of infusion. Although much about analgesics
in neonates is already known, further research is required
to ensure that the doses recommended for the treatment of
analgesia in neonates are evidence-based.
Schmidt et al52 compared the sufentanil versus fentanyl
in ventilated term neonates. These authors compared the
weaning time between fentanyl and sufentanil group.
Mean  SD weaning time of the fentanyl group was
520  381 minutes and of the sufentanil group was
585  531 minutes. No difference was observed for weaning
time between the fentanyl group and sufentanil group. The
mean opioid dose resulted in a 10:1 ratio (fentanyl 4.11 mg/
kg/hour vs. 0.41 mg/kg/hour). These authors found no dif-
ference in sedation levels, blood pressure, heart rate,
oxygenation index, comedication, or urinary cortisol levels.
In both groups similar adverse effects were assessed
including respiratory depression, mild withdrawal symp-
toms, or decrease of gastrointestinal motility.Conflicts of interest
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